ALXO vs. AVIR, IMAB, DCPH, MRVI, RYTM, GERN, VERA, AMPH, AGIO, and AMRX
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Atea Pharmaceuticals (AVIR), I-Mab (IMAB), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Atea Pharmaceuticals (NASDAQ:AVIR) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Atea Pharmaceuticals has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ALX Oncology received 24 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 62.12% of users gave ALX Oncology an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
In the previous week, ALX Oncology had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for ALX Oncology and 2 mentions for Atea Pharmaceuticals. ALX Oncology's average media sentiment score of 0.94 beat Atea Pharmaceuticals' score of 0.11 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.
Atea Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
ALX Oncology has a consensus price target of $18.83, suggesting a potential upside of 77.17%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Atea Pharmaceuticals.
ALX Oncology's return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 33.4% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
ALX Oncology beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
